GD2 Ganglioside (BioDeep_00000179362)

   

human metabolite blood metabolite


代谢物信息卡片


5-Amino-2-[3-(3-amino-6-carboxy-6-{[3-({4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl}oxy)-6-{[4,5-dihydroxy-6-({3-hydroxy-2-[(1-hydroxyoctadecylidene)amino]octadec-4-en-1-yl}oxy)-2-(hydroxymethyl)oxan-3-yl]oxy}-5-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxyoxan-2-yl)-2,3-dihydroxypropoxy]-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylate

化学式: C74H134N4O32 (1590.8980724)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCCCCCCCCCCCCCCCCC(=O)NC(COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3NC(C)=O)C(OC3(CC(O)C(N)C(O3)C(O)C(O)COC3(CC(O)C(N)C(O3)C(O)C(O)CO)C(O)=O)C(O)=O)C2O)C(O)C1O)C(O)C=CCCCCCCCCCCCCC
InChI: InChI=1S/C74H134N4O32/c1-4-6-8-10-12-14-16-18-19-21-23-25-27-29-31-33-52(89)78-43(44(84)32-30-28-26-24-22-20-17-15-13-11-9-7-5-2)40-101-69-61(95)60(94)63(50(38-81)104-69)106-70-62(96)67(64(51(39-82)105-70)107-68-55(77-42(3)83)59(93)58(92)49(37-80)103-68)110-74(72(99)100)35-46(86)54(76)66(109-74)57(91)48(88)41-102-73(71(97)98)34-45(85)53(75)65(108-73)56(90)47(87)36-79/h30,32,43-51,53-70,79-82,84-88,90-96H,4-29,31,33-41,75-76H2,1-3H3,(H,77,83)(H,78,89)(H,97,98)(H,99,100)

描述信息

同义名列表

3 个代谢物同义名

5-Amino-2-[3-(3-amino-6-carboxy-6-{[3-({4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl}oxy)-6-{[4,5-dihydroxy-6-({3-hydroxy-2-[(1-hydroxyoctadecylidene)amino]octadec-4-en-1-yl}oxy)-2-(hydroxymethyl)oxan-3-yl]oxy}-5-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxyoxan-2-yl)-2,3-dihydroxypropoxy]-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylate; 5-amino-6-(3-{[5-amino-2-carboxy-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxan-2-yl]oxy}-1,2-dihydroxypropyl)-2-{[2-({4,5-dihydroxy-6-[(3-hydroxy-2-octadecanamidooctadec-4-en-1-yl)oxy]-2-(hydroxymethyl)oxan-3-yl}oxy)-5-{[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxyoxane-2-carboxylic acid; GD2 Ganglioside



数据库引用编号

2 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Christine M Busch, Frank M Balis. Age-dependent reference intervals in children for the disialoganglioside, GD2, a circulating tumor biomarker for the childhood cancer, neuroblastoma. Clinical biochemistry. 2022 Mar; 101(?):1-4. doi: 10.1016/j.clinbiochem.2021.12.007. [PMID: 34929151]
  • Irene Y Cheung, Nai-Kong V Cheung, Shakeel Modak, Audrey Mauguen, Yi Feng, Ellen Basu, Stephen S Roberts, Govind Ragupathi, Brian H Kushner. Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 01; 39(3):215-226. doi: 10.1200/jco.20.01892. [PMID: 33326254]
  • Frank Milton Balis, Christine Maria Busch, Ami Vijay Desai, Emily Hibbitts, Arlene Naranjo, Rochelle Bagatell, Meredith Irwin, Elizabeth Fox. The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma. Pediatric blood & cancer. 2020 01; 67(1):e28031. doi: 10.1002/pbc.28031. [PMID: 31612589]
  • C M Busch, A V Desai, G S Moorthy, E Fox, F M Balis. A validated HPLC-MS/MS method for estimating the concentration of the ganglioside, GD2, in human plasma or serum. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2018 Dec; 1102-1103(?):60-65. doi: 10.1016/j.jchromb.2018.10.010. [PMID: 30368044]
  • Taiji Iwasawa, Pu Zhang, Yuki Ohkawa, Hiroyuki Momota, Toshihiko Wakabayashi, Yuhsuke Ohmi, Robiul H Bhuiyan, Keiko Furukawa, Koichi Furukawa. Enhancement of malignant properties of human glioma cells by ganglioside GD3/GD2. International journal of oncology. 2018 Apr; 52(4):1255-1266. doi: 10.3892/ijo.2018.4266. [PMID: 29436609]
  • Shima Gholizadeh, Emmy M Dolman, Rebecca Wieriks, Rolf W Sparidans, Wim E Hennink, Robbert J Kok. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells. Pharmaceutical research. 2018 Mar; 35(4):85. doi: 10.1007/s11095-018-2373-x. [PMID: 29516187]
  • Sharareh Gholamin, Hamed Mirzaei, Seyed-Mostafa Razavi, Seyed Mahdi Hassanian, Leila Saadatpour, Aria Masoudifar, Soodabeh ShahidSales, Amir Avan. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. Journal of cellular physiology. 2018 Feb; 233(2):866-879. doi: 10.1002/jcp.25793. [PMID: 28145567]
  • Yuhsuke Ohmi, Mariko Kambe, Yuki Ohkawa, Kazunori Hamamura, Orie Tajima, Rika Takeuchi, Koichi Furukawa, Keiko Furukawa. Differential roles of gangliosides in malignant properties of melanomas. PloS one. 2018; 13(11):e0206881. doi: 10.1371/journal.pone.0206881. [PMID: 30462668]
  • Nina Deppisch, Peter Ruf, Nina Eissler, Frauke Neff, Raymund Buhmann, Horst Lindhofer, Ralph Mocikat. Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery. Molecular cancer therapeutics. 2015 Aug; 14(8):1877-83. doi: 10.1158/1535-7163.mct-15-0156. [PMID: 26063765]
  • Wenyong Tong, Mario Maira, Martin Gagnon, H Uri Saragovi. Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology. PloS one. 2015; 10(8):e0134255. doi: 10.1371/journal.pone.0134255. [PMID: 26252487]
  • Ami V Desai, Elizabeth Fox, L Mary Smith, Allison Pecha Lim, John M Maris, Frank M Balis. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer chemotherapy and pharmacology. 2014 Nov; 74(5):1047-55. doi: 10.1007/s00280-014-2575-9. [PMID: 25212536]
  • Sarah M Cheal, Hong Xu, Hong-fen Guo, Pat B Zanzonico, Steven M Larson, Nai-Kong Cheung. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Molecular cancer therapeutics. 2014 Jul; 13(7):1803-12. doi: 10.1158/1535-7163.mct-13-0933. [PMID: 24944121]
  • Brandon S Brown, Tariq Patanam, Keyan Mobli, Christian Celia, Peter E Zage, Andrew J Bean, Ennio Tasciotti. Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies. Cancer biology & therapy. 2014 Jul; 15(7):851-61. doi: 10.4161/cbt.28875. [PMID: 24755919]
  • Qianyang Huang, Xiang Zhou, Danting Liu, Baozhong Xin, Karen Cechner, Heng Wang, Aimin Zhou. A new liquid chromatography/tandem mass spectrometry method for quantification of gangliosides in human plasma. Analytical biochemistry. 2014 Jun; 455(?):26-34. doi: 10.1016/j.ab.2014.03.014. [PMID: 24680754]
  • Nikolai Siebert, Christin Eger, Diana Seidel, Madlen Jüttner, Holger N Lode. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO. Journal of immunological methods. 2014 May; 407(?):108-15. doi: 10.1016/j.jim.2014.04.001. [PMID: 24727144]
  • P A Vishniakova, I I Doronin, I V Holodenko, D Iu Riazantsev, I M Molotkovskaia, R V Holodenko. [Caspases participarion in the cell death induced by GD2-specific monoclonal antibody]. Bioorganicheskaia khimiia. 2014 May; 40(3):305-14. doi: NULL. [PMID: 25898737]
  • Igor I Doronin, Polina A Vishnyakova, Irina V Kholodenko, Eugene D Ponomarev, Dmitry Y Ryazantsev, Irina M Molotkovskaya, Roman V Kholodenko. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC cancer. 2014 Apr; 14(?):295. doi: 10.1186/1471-2407-14-295. [PMID: 24773917]
  • Nikolai Siebert, Diana Seidel, Christin Eger, Madlen Jüttner, Holger N Lode. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody. PloS one. 2014; 9(9):e107692. doi: 10.1371/journal.pone.0107692. [PMID: 25226154]
  • Nikolai Siebert, Diana Seidel, Christin Eger, Diana Brackrock, Daniel Reker, Manuela Schmidt, Holger N Lode. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. Journal of immunological methods. 2013 Dec; 398-399(?):51-9. doi: 10.1016/j.jim.2013.09.008. [PMID: 24055592]
  • L Liebsch, S Kailayangiri, L Beck, B Altvater, R Koch, C Dierkes, M Hotfilder, N Nagelmann, C Faber, H Kooijman, J Ring, V Vieth, C Rossig. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. British journal of cancer. 2013 Aug; 109(3):658-66. doi: 10.1038/bjc.2013.356. [PMID: 23839490]
  • Aurélie Cazet, Marie Bobowski, Yoann Rombouts, Jonathan Lefebvre, Agata Steenackers, Iuliana Popa, Yann Guérardel, Xuefen Le Bourhis, David Tulasne, Philippe Delannoy. The ganglioside G(D2) induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the G(D3) synthase. Glycobiology. 2012 Jun; 22(6):806-16. doi: 10.1093/glycob/cws049. [PMID: 22301273]
  • Katherine K Matthay, Rani E George, Alice L Yu. Promising therapeutic targets in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 May; 18(10):2740-53. doi: 10.1158/1078-0432.ccr-11-1939. [PMID: 22589483]
  • Richard Schäfer, Martina Schnaidt, Roland A Klaffschenkel, Georg Siegel, Michael Schüle, Maria Anna Rädlein, Ursula Hermanutz-Klein, Miriam Ayturan, Marine Buadze, Christoph Gassner, Lusine Danielyan, Torsten Kluba, Hinnak Northoff, Willy A Flegel. Expression of blood group genes by mesenchymal stem cells. British journal of haematology. 2011 May; 153(4):520-8. doi: 10.1111/j.1365-2141.2011.08652.x. [PMID: 21418181]
  • Makoto Yanagisawa, Saori Yoshimura, Robert K Yu. Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells. ASN neuro. 2011 Apr; 3(2):. doi: 10.1042/an20110006. [PMID: 21395555]
  • Soumika Biswas, Kaushik Biswas, Amy Richmond, Jennifer Ko, Sankar Ghosh, Matthew Simmons, Patricia Rayman, Brian Rini, Inderbir Gill, Charles S Tannenbaum, James H Finke. Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. Journal of immunology (Baltimore, Md. : 1950). 2009 Oct; 183(8):5050-8. doi: 10.4049/jimmunol.0900259. [PMID: 19801523]
  • Dominik Czaplicki, Irena Horwacik, Aleksandra Kowalczyk, Aleksandra Wieczorek, Katarzyna Bolek-Marzec, Walentyna Balwierz, Andrzej Kozik, Hanna Rokita. New method for quantitative analysis of GD2 ganglioside in plasma of neuroblastoma patients. Acta biochimica Polonica. 2009; 56(3):423-31. doi: 10.18388/abp.2009_2476. [PMID: 19724779]
  • Martina M Uttenreuther-Fischer, Jörg A Krüger, Peter Fischer. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?. Journal of immunology (Baltimore, Md. : 1950). 2006 Jun; 176(12):7775-86. doi: 10.4049/jimmunol.176.12.7775. [PMID: 16751426]
  • S Marconi, M Acler, L Lovato, L De Toni, E Tedeschi, E Anghileri, S Romito, C Cordioli, B Bonetti. Anti-GD2-like IgM autoreactivity in multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England). 2006 Jun; 12(3):302-8. doi: 10.1191/135248506ms1279oa. [PMID: 16764343]
  • Wei Aixinjueluo, Keiko Furukawa, Qing Zhang, Kazunori Hamamura, Noriyo Tokuda, Shoko Yoshida, Ryuzo Ueda, Koichi Furukawa. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. The Journal of biological chemistry. 2005 Aug; 280(33):29828-36. doi: 10.1074/jbc.m414041200. [PMID: 15923178]
  • Elizabeth Bolesta, Aleksandra Kowalczyk, Andrzej Wierzbicki, Piotr Rotkiewicz, Barbara Bambach, Chun-Yen Tsao, Irena Horwacik, Andrzej Kolinski, Hanna Rokita, Martin Brecher, Xinhui Wang, Soldano Ferrone, Danuta Kozbor. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer research. 2005 Apr; 65(8):3410-8. doi: 10.1158/0008-5472.can-04-2164. [PMID: 15833876]
  • Chiara Brignole, Fabio Pastorino, Danilo Marimpietri, Gabriella Pagnan, Angela Pistorio, Theresa M Allen, Vito Pistoia, Mirco Ponzoni. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. Journal of the National Cancer Institute. 2004 Aug; 96(15):1171-80. doi: 10.1093/jnci/djh221. [PMID: 15292389]
  • Govind Ragupathi, Philip O Livingston, Chandra Hood, John Gathuru, Susan E Krown, Paul B Chapman, Jedd D Wolchok, Linda J Williams, Roberta C Oldfield, Wen-Jen Hwu. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Nov; 9(14):5214-20. doi: NULL. [PMID: 14614001]
  • Ikuo Kawashima, Yukiko Yoshida, Chouji Taya, Hiroshi Shitara, Hiromichi Yonekawa, Hajime Karasuyama, Nobuhiko Tada, Koichi Furukawa, Tadashi Tai. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells. International journal of oncology. 2003 Aug; 23(2):381-8. doi: 10.3892/ijo.23.2.381. [PMID: 12851687]
  • Chiara Brignole, Gabriella Pagnan, Danilo Marimpietri, Emilio Cosimo, Theresa M Allen, Mirco Ponzoni, Fabio Pastorino. Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer letters. 2003 Jul; 197(1-2):231-5. doi: 10.1016/s0304-3835(03)00107-1. [PMID: 12880987]
  • Kotaro Mizutani, Nobuyuki Oka, Susumu Kusunoki, Ryuji Kaji, Masutaro Kanda, Ichiro Akiguchi, Hiroshi Shibasaki. Amyotrophic lateral sclerosis with IgM antibody against gangliosides GM2 and GD2. Internal medicine (Tokyo, Japan). 2003 Mar; 42(3):277-80. doi: 10.2169/internalmedicine.42.277. [PMID: 12705795]
  • Jacquelyn A Hank, Jean E Surfus, Jacek Gan, Amy Ostendorf, Stephen D Gillies, Paul M Sondel. Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine. Methods in molecular medicine. 2003; 85(?):123-31. doi: 10.1385/1-59259-380-1:123. [PMID: 12710203]
  • Patricia Guerry, Christine M Szymanski, Martina M Prendergast, Thomas E Hickey, Cheryl P Ewing, Dawn L Pattarini, Anthony P Moran. Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro. Infection and immunity. 2002 Feb; 70(2):787-93. doi: 10.1128/iai.70.2.787-793.2002. [PMID: 11796612]
  • N K Cheung, H F Guo, G Heller, I Y Cheung. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Jul; 6(7):2653-60. doi: NULL. [PMID: 10914706]
  • N Hanai, K Nakamura, K Shitara. Recombinant antibodies against ganglioside expressed on tumor cells. Cancer chemotherapy and pharmacology. 2000; 46 Suppl(?):S13-7. doi: 10.1007/pl00014042. [PMID: 10950141]
  • I Bergman, C R Pohl, R Venkataramanan, G J Burckart, M Stabin, M A Barmada, J A Griffin, N K Cheung. Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats. Journal of immunotherapy (Hagerstown, Md. : 1997). 1999 Mar; 22(2):114-23. doi: 10.1097/00002371-199903000-00003. [PMID: 10093036]
  • N K Cheung, B H Kushner, I Y Cheung, K Kramer, A Canete, W Gerald, M A Bonilla, R Finn, S J Yeh, S M Larson. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Sep; 16(9):3053-60. doi: 10.1200/jco.1998.16.9.3053. [PMID: 9738575]
  • P Heiss, S Bermatz, H Wehnes, U Heinzmann, R Senekowitsch-Schmidtke. Distribution of disialoganglioside GD2-antigen and binding of anti-GD2 antibodies on spheroids of neuroblastoma cell line. Anticancer research. 1997 Jul; 17(4B):3145-7. doi: NULL. [PMID: 9329622]
  • W H Xiao, A L Yu, L S Sorkin. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain. 1997 Jan; 69(1-2):145-51. doi: 10.1016/s0304-3959(96)03280-0. [PMID: 9060025]
  • M R Albertini, J Gan, P Jaeger, J A Hank, B Storer, K Schell, T Rivest, J Surfus, R A Reisfeld, J H Schiller, P M Sondel. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 1996 Jul; 19(4):278-95. doi: 10.1097/00002371-199607000-00004. [PMID: 8877722]
  • S C Grant, L Kostakoglu, M G Kris, S D Yeh, S M Larson, R D Finn, H F Oettgen, N V Cheung. Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. European journal of nuclear medicine. 1996 Feb; 23(2):145-9. doi: 10.1007/bf01731837. [PMID: 8925848]
  • M M Uttenreuther-Fischer, C S Huang, R A Reisfeld, A L Yu. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer immunology, immunotherapy : CII. 1995 Jul; 41(1):29-36. doi: 10.1007/bf01788957. [PMID: 7641217]
  • B Schaber, G Bruchelt, J Meyle, B Jeschke, R Handgretinger, D Niethammer, P Mayer, G Rassner, G Fierlbeck. Chemotactic activity of substances derived from antibody-loaded tumor cells on granulocytes. Immunology letters. 1994 Jun; 41(1):67-71. doi: 10.1016/0165-2478(94)90058-2. [PMID: 7959905]
  • N K Cheung, I Y Cheung, A Canete, S J Yeh, B Kushner, M A Bonilla, G Heller, S M Larson. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer research. 1994 Apr; 54(8):2228-33. doi: NULL. [PMID: 8174131]
  • P Mayer, R Handgretinger, G Bruchelt, B Schaber, G Rassner, G Fierlbeck. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a. Melanoma research. 1994 Apr; 4(2):101-6. doi: 10.1097/00008390-199404000-00004. [PMID: 8069095]
  • J A Hank, J Surfus, J Gan, T L Chew, R Hong, K Tans, R Reisfeld, R C Seeger, C P Reynolds, M Bauer. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 1994 Jan; 15(1):29-37. doi: 10.1097/00002371-199401000-00004. [PMID: 8110728]
  • N K Cheung, A Canete, I Y Cheung, J N Ye, C Liu. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. International journal of cancer. 1993 May; 54(3):499-505. doi: 10.1002/ijc.2910540324. [PMID: 8509225]
  • J Portoukalian, M J David, P Gain, M Richard. Shedding of GD2 ganglioside in patients with retinoblastoma. International journal of cancer. 1993 Apr; 53(6):948-51. doi: 10.1002/ijc.2910530614. [PMID: 8473052]
  • M N Saleh, M B Khazaeli, R H Wheeler, E Dropcho, T Liu, M Urist, D M Miller, S Lawson, P Dixon, C H Russell. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer research. 1992 Aug; 52(16):4342-7. doi: NULL. [PMID: 1643631]
  • A Rosenberg, A Sauer, E P Noble, H J Gross, R Chang, R Brossmer. Developmental patterns of ganglioside sialosylation coincident with neuritogenesis in cultured embryonic chick brain neurons. The Journal of biological chemistry. 1992 May; 267(15):10607-12. doi: 10.1016/s0021-9258(19)50060-6. [PMID: 1587841]
  • N Yuki, N Miyatani, S Sato, Y Hirabayashi, M Yamazaki, N Yoshimura, Y Hayashi, T Miyatake. Acute relapsing sensory neuropathy associated with IgM antibody against B-series gangliosides containing a GalNAc beta 1-4(Gal3-2 alpha NeuAc8-2 alpha NeuAc)beta 1 configuration. Neurology. 1992 Mar; 42(3 Pt 1):686-9. doi: 10.1212/wnl.42.3.686. [PMID: 1549241]
  • R Handgretinger, P Baader, R Dopfer, T Klingebiel, P Reuland, J Treuner, R A Reisfeld, D Niethammer. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer immunology, immunotherapy : CII. 1992; 35(3):199-204. doi: 10.1007/bf01756188. [PMID: 1638557]
  • B M Mueller, R A Reisfeld, S D Gillies. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proceedings of the National Academy of Sciences of the United States of America. 1990 Aug; 87(15):5702-5. doi: 10.1073/pnas.87.15.5702. [PMID: 2198570]
  • H Yamaguchi, K Furukawa, S R Fortunato, P O Livingston, K O Lloyd, H F Oettgen, L J Old. Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient. Proceedings of the National Academy of Sciences of the United States of America. 1990 May; 87(9):3333-7. doi: 10.1073/pnas.87.9.3333. [PMID: 2159145]
  • B A Sela, D Iliopoulos, D Guerry, D Herlyn, H Koprowski. Levels of disialogangliosides in sera of melanoma patients monitored by sensitive thin-layer chromatography and immunostaining. Journal of the National Cancer Institute. 1989 Oct; 81(19):1489-92. doi: 10.1093/jnci/81.19.1489. [PMID: 2778837]
  • N K Cheung, H Lazarus, F D Miraldi, C R Abramowsky, S Kallick, U M Saarinen, T Spitzer, S E Strandjord, P F Coccia, N A Berger. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1987 Sep; 5(9):1430-40. doi: 10.1200/jco.1987.5.9.1430. [PMID: 3625258]
  • T Yamanaka, Y Hirabayashi, M Hirota, M Kaneko, M Matsumoto, N Kobayashi. Detection of gangliotriaose-series glycosphingolipids in serum of cord blood and patients with neuroblastoma by a sensitive TLC/enzyme-immunostaining method. Biochimica et biophysica acta. 1987 Jul; 920(2):181-4. doi: . [PMID: 3300782]
  • S Ladisch, Z L Wu, S Feig, L Ulsh, E Schwartz, G Floutsis, F Wiley, C Lenarsky, R Seeger. Shedding of GD2 ganglioside by human neuroblastoma. International journal of cancer. 1987 Jan; 39(1):73-6. doi: 10.1002/ijc.2910390113. [PMID: 3539825]
  • D A Cheresh, F G Klier. Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. The Journal of cell biology. 1986 May; 102(5):1887-97. doi: 10.1083/jcb.102.5.1887. [PMID: 3084502]
  • P Hersey, A Edwards, G D'Alessandro, M MacDonald. Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients. Cancer immunology, immunotherapy : CII. 1986; 22(3):221-31. doi: 10.1007/bf00200037. [PMID: 3460702]
  • G Schulz, D A Cheresh, N M Varki, A Yu, L K Staffileno, R A Reisfeld. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer research. 1984 Dec; 44(12 Pt 1):5914-20. doi: NULL. [PMID: 6498849]
  • T Tai, L D Cahan, J C Paulson, R E Saxton, R F Irie. Human monoclonal antibody against ganglioside GD2: use in development of enzyme-linked immunosorbent assay for the monitoring of anti-GD2 in cancer patients. Journal of the National Cancer Institute. 1984 Sep; 73(3):627-33. doi: NULL. [PMID: 6206271]